601. Therapeutic effect of yttrium oxide nanoparticles for the treatment of fulminant hepatic failure.
- Author
-
Song X, Shang P, Sun Z, Lu M, You G, Yan S, Chen G, and Zhou H
- Subjects
- Animals, Antioxidants chemistry, Apoptosis drug effects, Galactosamine toxicity, Gene Expression Regulation drug effects, Humans, Lipid Peroxidation, Lipopolysaccharides toxicity, Liver drug effects, Liver pathology, Liver Failure, Acute chemically induced, Liver Failure, Acute pathology, Mice, NF-kappa B genetics, Nanoparticles chemistry, RAW 264.7 Cells, Reactive Oxygen Species metabolism, Yttrium chemistry, Liver Failure, Acute drug therapy, Nanoparticles administration & dosage, Oxidative Stress drug effects, Yttrium pharmacology
- Abstract
Aim: To explore the potential therapeutic effect of yttrium oxide nanoparticles (Y
2 O3 NPs) on fulminant hepatic failure. Materials & methods: RAW264.7 cells and a lipopolysaccharide/D-galactosamine-induced hepatic failure murine model were used to assess the effects of Y2 O3 NPs. Results: Y2 O3 NPs exhibited anti-inflammatory activity by scavenging cellular reactive oxygen species and dampening reactive oxygen species-mediated NF-κB activation in vitro . A single intraperitoneal administration of Y2 O3 NPs (30 mg/kg) enhanced hepatic antioxidant status and reduced oxidative stress and inflammatory response in lipopolysaccharide/galactosamine-induced mice. Y2 O3 NPs also attenuated hepatic NF-κB activation, cell apoptosis and liver injury. Conclusion: Y2 O3 NP administration could be used as a novel therapeutic strategy for treating fulminant hepatic failure and oxidative stress-related diseases.- Published
- 2019
- Full Text
- View/download PDF